Investigational drug · Phase 3
IDRX-42
Also called: velzatinib - subject to USAN approval
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastrointestinal Neoplasms.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
7
Any phase or sponsor naming "IDRX-42"
First trial start
2025
Dec 3, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IDRX-42", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastrointestinal Neoplasms
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "IDRX-42" as an intervention, largest first.
- A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib TherapyPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07218926 · 450 participants (planned) · Start Dec 3, 2025 · Primary completion May 30, 2028
Drug: IDRX-42; Sunitinib · For: Gastrointestinal Neoplasms
Sites: Phoenix, Arizona; Duarte, California; La Jolla, California · 156 sites in all
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal TumorsActive, not recruiting
IDRX, Inc., a wholly owned subsidiary of GSK, LLCIndustry
NCT05489237 · 276 participants · Start Aug 3, 2022 · Primary completion Mar 10, 2027
Drug: IDRX-42 · For: Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumor (GIST); Digestive System Disease and 2 more
Sites: Miami, Florida; Chicago, Illinois; Boston, Massachusetts · 31 sites in all
GlaxoSmithKlineGSK (GSK)
NCT07859735 · 40 participants (planned) · Start Nov 10, 2026 · Primary completion Apr 25, 2028
Drug: Velzatinib · For: Healthy Participants; Gastrointestinal Neoplasms
- A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07862114 · 36 participants (planned) · Start Oct 16, 2026 · Primary completion Jan 12, 2027
Drug: Velzatinib; Cyclosporine and 1 more · For: Healthy Participants; Gastrointestinal Neoplasms
- A Study to Investigate the Effects of Moderate or Severe Renal Impairment (RI) on VelzatinibNot yet recruiting
GlaxoSmithKlineGSK (GSK)
NCT07867171 · 30 participants (planned) · Start Oct 23, 2026 · Primary completion Sep 9, 2027
Drug: Velzatinib · For: Healthy Participants; Gastrointestinal Neoplasms
GlaxoSmithKlineGSK (GSK)
NCT07689201 · 24 participants (planned) · Start Aug 17, 2026 · Primary completion Nov 29, 2027
Drug: Velzatinib · For: Gastrointestinal Neoplasms
Sites: Fukuoka, Japan; Hokkaido, Japan; Tokyo, Japan
GlaxoSmithKlineGSK (GSK)
NCT07825701
Drug: Velzatinib (GSK6042981) · For: Gastrointestinal Neoplasms
Newest research
PubMed records naming it or its code names, newest first.
- Tyrosine Kinase Inhibitors for Gastrointestinal Stromal Tumor After Imatinib Resistance.
Xiao XH, Zhang QS, Hu JY, et al. · Pharmaceutics 2025
- M4205 (IDRX-42) Is a Highly Selective and Potent Inhibitor of Relevant Oncogenic Driver and Resistance Variants of KIT in Cancer.
Esdar C, Linde N, Blum A, et al. · Mol Cancer Ther 2025
- Emerging treatments for sarcoma: from 2024 onward.
Gómez-Puerto D, Cicala CM, Valverde C, et al. · Expert Opin Emerg Drugs 2025
- KIT/PDGFRA inhibitors for the treatment of gastrointestinal stromal tumors: getting to the gist of the problem.
Cicala CM, Olivares-Rivas I, Aguirre-Carrillo JA, et al. · Expert Opin Investig Drugs 2024
- Antitumor Efficacy of the Novel KIT Inhibitor IDRX-42 (Formerly M4205) in Patient- and Cell Line-Derived Xenograft Models of Gastrointestinal Stromal Tumor (GIST).
De Sutter L, Wozniak A, Verreet J, et al. · Clin Cancer Res 2023
- Identification of M4205ৄA Highly Selective Inhibitor of KIT Mutations for Treatment of Unresectable Metastatic or Recurrent Gastrointestinal Stromal Tumors.
Blum A, Dorsch D, Linde N, et al. · J Med Chem 2023
Also in development for Gastrointestinal Neoplasms
- HS-20093Ris-Rez, Risvutatug rezetecanPhase 316 trials
Hansoh BioMedical R&D Company · Neoplasms, Lung, Sarcoma, Osteosarcoma
- VelzatinibGSK6042981Phase 33 trials
GSK · Gastrointestinal Neoplasms, Gastrointestinal Stromal Neoplasms
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.